Severe cardiomyopathy induced by Adalimumab administration for Crohn’s disease

Ali Toufaily1,2*
1Division of Cardiology, Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon
2Division of Cardiology, Rafik Hariri University Hospital, Beirut, Lebanon

Abstract
The use of tumor necrosis factor alpha inhibitors anti-TNFa (infliximab, adalimumab, and certolizumab) in the treatment of inflammatory bowel disease (IBD) provide a major therapeutic advance, allowing significant benefits in the induction and maintenance of remission in Crohn’s disease [1-3]. However, the safety-profile of TNF inhibitors with regard to worsening or new onset of heart failure is still very controversial. Consequently, there has been a lot of attention paid to the risk of cardiovascular side effects associated with adalimumab therapy [4-6]. A 42-year-old woman treated with adalimumab for severe Crohn’s disease exacerbation; 8 days after the second dose of adalimumab (80mg), she presented with dramatic clinical features of heart failure and pulmonary edema. Echocardiography demonstrated severely depressed left ventricle contractility with ejection fraction 35%; cardiac MRI revealed no gadolinium enhancement (no ischemia, no myocarditis). Adalimumab was discontinued, and patient was treated with evidence-based oral disease-modifying HF therapy; 2 months later, cardiac function has returned to normal. This case clearly demonstrated the acute onset of decompensated heart failure with adalimumab usage.

Introduction
Inhibitors of tumor necrosis factor (TNF)-alpha (adalimumab) offer an important targeted therapy in a large number of inflammatory conditions, including rheumatoid arthritis (RA), psoriasis, spondyloarthritis and inflammatory bowel disease (IBD) [7,8]. In fact, the effectiveness of those drugs has been well established. However, multiple adverse effects have been identified through both clinical trials and post-marketing surveillance, ranging from benign to serious side effect such as lymphomas, infections (especially reactivation of latent tuberculosis), demyelinating disease and cardiomyopathy which are associated with substantial mortality [9,10].

Case Report
A 42-year-old woman, former smoker, non-alcoholic has been diagnosed with Crohn’s disease since teenage, maintained on azathioprine. Apart from her gastro-intestinal symptoms, her prior medical history was unremarkable. She was admitted to our ward for profuse watery diarrhea with abdominal pain, managed as acute exacerbation of her Crohn’s disease. At that time adalimumab 160 mg was initiated and she had improved a lot from her baseline. Two weeks later, she received a dose of 80 mg subcutaneous injection according to the universal treatment regimen of adalimumab, then after 8 days, she presented to our ER department with severe shortness of breath, palpitation, cough, and desaturation. Echocardiographic examination showed severe left ventricle function impairment with ejection fraction 35%; cardiac MRI revealed no gadolinium enhancement (no ischemia, no myocarditis). Adalimumab was discontinued, and patient was treated with evidence-based oral disease-modifying HF therapy; 2 months later, cardiac function has returned to normal. This case clearly demonstrated the acute onset of decompensated heart failure with adalimumab usage.

Figure 1. Normal angiogram

Coronary angiography was made showing non stenotic coronaries (Figure 1). Cardiac MRI confirmed the impaired global contractility of the LV, with no late gadolinium enhancement (Figure 2).Taking into consideration the last echocardiography performed 1 month ago which was totally normal in addition to non-specific MRI features obtained, as an exclusion diagnosis, adalimumab was considered as the cause of the acute decompensated heart failure. Patient was placed on optimal heart failure therapy then discharged after appropriate stabilization.

Adalimumab remained certainly withdrawn then 2 months later, repeated echocardiography demonstrated a full recovery.

*Correspondence to: Ali Toufaily, Division of Cardiology, Faculty of Medical Sciences, Lebanese University, Lebanon, E-mail: alitfayli81@gmail.com

Key words: TNF-a inhibitor, adalimumab, heart failure, crohn’s disease

Received: December 16, 2019; Accepted: December 26, 2019; Published: January 03, 2020
Discussion and Conclusion

Adalimumab have dramatically improved the therapy of many inflammatory diseases and led to major progress not only for patients with Crohn’s disease but also for those with ulcerative colitis, psoriasis, ankylosing spondylitis and rheumatoid arthritis [11-13]. Common side effects such as headache, rash and nausea are usually well tolerated and self-limiting and generally do not lead to drug discontinuation. However, disabling and potentially life-threatening side effects occurred as well, particularly opportunistic infection, tumor development, and cardiotoxicity. Although adalimumab induced tachyarrhythmias, hypertension or palpitation were frequently reported, the link between TNF blockade and moderate to severe congestive heart failure remains controversial [14,15]. In daily practice, the physicians must at all times be alert to the possible occurrence of adalimumab induced cardiomyopathy after careful exclusion of others etiologies such as myocarditis, myocardial infarction, stress induced cardiomyopathy. In conclusion, further research seems to be warranted to well define the cardiotoxicity profile of adalimumab.

References